Tonix Pharmaceuticals  reports Q2 net loss of  $28.3 mln

Tonix Pharmaceuticals Holding

11/08/2025 21:35

Overview

Tonix Q2 reports net loss of $28.3 mln, compared to net loss of $78.8 million last year

Reports basic EPS of -$3.86

Company's cash position improves to $125.3 mln, funding operations into Q3 2026

Outlook

Tonix expects FDA decision on TNX-102 SL by August 15, 2025

Company anticipates cash runway to fund operations into Q3 2026

Tonix preparing for potential TNX-102 SL commercialization in Q4 2025

Result Drivers

TNX-102 SL - Phase 3 results show significant pain reduction in fibromyalgia patients, supporting NDA review

INCREASED EXPENSES - Higher SG&A expenses due to pre-launch activities for TNX-102 SL

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$28.27 mln
Q2 Basic EPS
-$3.86
-$3.21 (2 Analysts)
Q2 Operating Income
-$28.30 mln
-$26.30 mln (1 Analyst)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $65.00, about 28.5% above its August 8 closing price of $46.49

Press Release: ID:nGNX5gt8L1

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)